The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo

被引：0
|
作者：
Anthony Tumber
Laura S. Collins
Kamille Dumong Petersen
Annemette Thougaard
Sanne J. Christiansen
Marielle Dejligbjerg
Peter Buhl Jensen
Maxwell Sehested
James W. A. Ritchie
机构：
[1] TopoTarget UK LTD,Finsen Centre
[2] TopoTarget A/S,Diagnostic Centre
[3] Symbion Science Park,undefined
[4] Rigshospitalet,undefined
[5] Rigshospitalet,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2007年 / 60卷
关键词：
Histone deacetylase inhibitors; Drug combinations; Synergy; 5-fluorouracil; Colorectal cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：275 / 283
页数：8
相关论文
共 50 条
  • [21] Combination of the proteasome inhibitor bortezomib and a histone deacetylase inhibitor PXD101 results in synergistic inhibition of osteoclastogenesis and significantly stronger inhibition of multiple myeloma growth in vitro and in vivo.
    Feng, Rentian
    Oton, Ana B.
    Patrene, Kenneth
    Anderson, Gulsum
    Mapara, Markus Y.
    Belani, Chandra
    Roodman, David
    Lentzsch, Suzanne
    BLOOD, 2006, 108 (11) : 153A - 154A
  • [22] Growth inhibition of renal cancer cells by histone deacetylase inhibitors, suberoylanilide hydroxamic acid (SAHA) and PXD101
    Min, Gyeong Eun
    Hwang, Jung Jin
    Yoo, Changhee
    Kim, Mi-Joung
    Kim, Yong-Sook
    Song, Kanghyon
    Kim, Seong Cheol
    Kwon, Taek Min
    Park, Jong Yeon
    Ahn, Tai Young
    Kim, Choung-Soo
    JOURNAL OF UROLOGY, 2008, 179 (04): : 40 - 40
  • [23] Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)
    Cashen, Amanda
    Juckett, Mark
    Jumonville, Alcee
    Litzow, Mark
    Flynn, P. J.
    Eckardt, John
    LaPlant, Betsy
    Laumann, Kristina
    Erlichman, Charles
    DiPersio, John
    ANNALS OF HEMATOLOGY, 2012, 91 (01) : 33 - 38
  • [24] A phase I study of the histone deacetylase (HDAC) inhibitor PXD101 in patients with advanced hematological tumors
    Hansen, M
    Gimsing, P
    Rasmussen, A
    Jensen, PB
    Knudsen, LM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 225S - 225S
  • [25] Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)
    Amanda Cashen
    Mark Juckett
    Alcee Jumonville
    Mark Litzow
    P. J. Flynn
    John Eckardt
    Betsy LaPlant
    Kristina Laumann
    Charles Erlichman
    John DiPersio
    Annals of Hematology, 2012, 91 : 33 - 38
  • [26] Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates
    Warren, Katherine E.
    McCully, Cindy
    Dvinge, Henrik
    Tjornelund, Jette
    Sehested, Maxwell
    Lichenstein, Henri S.
    Balis, Frank M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (03) : 433 - 437
  • [27] Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates
    Katherine E. Warren
    Cindy McCully
    Henrik Dvinge
    Jette Tjørnelund
    Maxwell Sehested
    Henri S. Lichenstein
    Frank M. Balis
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 433 - 437
  • [28] Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines
    Iwahashi, Shuichi
    Ishibashi, Hiroki
    Utsunomiya, Tohru
    Morine, Yuji
    Ochir, Tovuu Lkhaguva
    Hanaoka, Jun
    Mori, Hiroki
    Ikemoto, Tetsuya
    Imura, Satoru
    Shimada, Mitsuo
    JOURNAL OF MEDICAL INVESTIGATION, 2011, 58 (1-2): : 106 - 109
  • [29] Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell line
    Yamada, Shinichiro
    Shimada, Mitsuo
    Utsunomiya, Tohru
    Morine, Yuji
    Imura, Satoru
    Ikemoto, Tetsuya
    Hanaoka, Jun
    Mori, Hiroki
    Kanamoto, Mami
    Iwahashi, Shuichi
    Saito, Yu
    Asanoma, Michihito
    CANCER RESEARCH, 2011, 71
  • [30] Plasma and cerobrospinal fluid (CSF) pharmacokinetics of the histone deacetylase (HDAC) inhibitor, PXD101, in non-human primates
    Warren, Katherine E.
    McCully, Cindy M.
    Dvinge, Henrik
    Sehested, Maxwell
    Tjornelund, Jette
    Lichenstein, Henri S.
    Balis, Frank M.
    CANCER RESEARCH, 2006, 66 (08)
12345